Guido Kroemer

USPTO Granted Patents = 16 (Patent Applications = 14)

EPO Patents = 6 (Patent Applications = 21)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 89(Granted Patents)

Location History:

Antony, FR (2012 - 2013)
Paris, FR (2001 - 2024)

Company Filing History:

8 out of 95

Institut Gustave Roussy

patents

8 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

patents

4 out of 5,072

Centre National De La Recherche Scientifique

Assistance Publique - Hopitaux De Paris (aphp)

patents

6. 2 out of 15

Université De Technologie De Compiègne

patents

7. 2 out of 52

Universite Paris Cité

UniversitÉ Paris Descartes

patents

12. 1 out of 67

Université Pierre Et Marie Curie

patents

13. 1 out of 1

Instituto Nazionale Per Le Malattie Infettie Irccs Lazzaro Spallanzani

patent

14. 1 out of 832,718

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12343376 - Methods for inhibiting diazepam binding protein (2025-07-01),

2. 11905330 - Methods for weight reduction (2024-02-20),

3. 11040052 - Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof (2021-06-22),

4. 10969380 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2021-04-06),

5. 9938528 - Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections (2018-04-10),

6. 9726661 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2017-08-08),

7. 8865653 - Method of treatment for immunogenic treatment resistant cancer (2014-10-21),

8. 8828944 - Compounds and uses thereof to induce an immunogenic cancer cell death in a subject (2014-09-09),

9. 8557517 - Toll like receptor 4 dysfunction and the biological applications thereof (2013-10-15),

10. 8263344 - Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment (2012-09-11),

11. 8129340 - Inhibitors of protein phosphatase 1, GADD34 and protein phosphatase 1/GADD34 complex, preparation and uses thereof (2012-03-06),

12. 7642051 - Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT) (2010-01-05),

13. 7371834 - Apoptosis-inducing factor (2008-05-13),

14. 7056735 - Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) (2006-06-06),

15. 6773911 - Apoptosis-inducing factor (2004-08-10),

Title: Innovator Spotlight: Guido Kroemer - Pioneering Autophagy Modulation for Weight Reduction

Introduction: Guido Kroemer, a renowned inventor based in Paris, FR, has made significant contributions to the field of autophagy modulation for weight reduction. With 15 patents to his name, Kroemer's groundbreaking research has paved the way for novel methods in the treatment of various diseases by targeting autophagy pathways.

Latest Patents: Kroemer's latest patents focus on methods for weight reduction through the modulation of autophagy. By identifying the role of diazepam binding inhibitor (DBI) in regulating autophagy, Kroemer and his team have developed pharmaceutical compositions for modulating autophagy in individuals requiring such treatment. Their research demonstrates the potential of DBI inhibition in enhancing glycolysis, lipogenesis, and metabolic changes that lead to weight loss.

Career Highlights: Kroemer has held key positions at prestigious institutions such as Institut Gustave Roussy and Centre National De La Recherche Scientifique. His dedication to advancing the understanding of autophagy and its therapeutic implications has earned him recognition in the scientific community.

Collaborations: Kroemer has collaborated with esteemed colleagues including Laurence Zitvogel and Jean-Luc Perfettini. Through collaborative efforts, Kroemer has been able to broaden the scope of his research and develop innovative solutions to complex medical challenges.

Conclusion: Guido Kroemer's pioneering work in autophagy modulation stands as a testament to his ingenuity and commitment to improving healthcare outcomes. His patents and research have significantly advanced the field of weight reduction and opened new avenues for treating autophagy-related diseases.

This text is generated by artificial intelligence and may not be accurate.